Andrew Musgrave
Welcome again to ASX Briefs, and today I'm joined by Dr. Tara Speranza, the CEO and CTO of Vectus Biosystems, a company which is a clinical stage biotech developing novel treatments for fibrotic diseases. Tara, thanks for joining me today and welcome to the ASX Briefs podcast.
Tara Speranza
Thanks very much, Andrew. It's my pleasure to be here.
Andrew Musgrave
Now, Tara, you formally stepped into the CEO and CTO role in May after working with Vectus as a consultant since August of last year. What did you see in the company that made you want to lead it and what has changed in how Vectus operates since you took the helm?
Tara Speranza: 00:42
Yeah, thanks for that question, Andrew. So, when I came on, I originally came in to help the company organize some of the data for a licensing deal that they were doing with the small Canadian biotech company. So, I helped organize and actually analyze some of that raw data to get the data room built so that the other company could take a look and send their scientists in to do their due diligence. And just like me, they saw the potential that the company had and how strong the data was. So, for me, I saw it not just with that drug that the Canadian company licensed out, but also for a number of the drugs that Vectus has in their portfolio. And I really didn't like to see the drugs being licensed out at such an early stage. I really felt like the potential was so great that it would be better off for the company and the incumbent shareholders to be able to put a bit more value into those assets or those drugs by pushing them through the pipeline or the development pipeline a bit further along before letting them go to other companies. For me, the data was really, really strong, and I was lucky in that I got to go right back and have a look at that raw data. You know, I was looking at slides of the animals' organs that had had fibrosis and then been treated with the drugs. So, it was as close as you could get to the actual animal work that I could have. And then the other thing is that not only that, but the company had already put the lead asset that I'm sure we're going to talk about in a moment through its GLP Tox studies and they were complete from woe to go. Every single required toxicology study had been done, the tox data and the pharmacology data looked really strong. And so, I said to the guys that on the board who had asked me, you know, after we'd executed that deal if I'd like to come in, I said to them, you know, with pleasure, but we really need to do a bit of a pivot because even though the drug's been doing so well up until the early clinical studies, the diseases that they were looking at are such big diseases. And I said to them that a company of this size, given that you have such nice data in animal models of lung fibrosis, the company should be going after an idiopathic pulmonary fibrosis disease or IPF, because it is, in my opinion, and the opinion of many KOLs that I speak to, an unmet need in that whilst there are a couple of drugs that are approved and on the market for IPF, these drugs are aimed at slowing the progression of the fibrosis in the lungs in this disease. And we had this data in animals that suggested that our drug actually reverses the fibrosis. And so, by doing that, we get sort of access to what we see as a rare disease, so a small number of patients, less than 200,000 in the US. And that provides companies, if the FDA agree with you, that is, that provides companies with a little bit of hand holding. So, they give you a little bit of help to get through those early clinical development milestones and so, you know, I got the board to sort of agree with me and we've started to pivot into that direction.
Andrew Musgrave
Now that lead asset that you mentioned, which is VB0004 for idiopathic pulmonary fibrosis, for new investors that are new to that story, what is IPF and why is there such a significant unmet need?
Tara Speranza
Yeah, great question. Thanks, Andrew. The IPF is a disease of fibrosis of the lungs. And that word, idiopathic, simply means we do not know what is causing this disease. So, this is not the same as lung fibrosis that we see in ex-smokers or in lung fibrosis that we see in people with silicosis or asbestosis-caused diseases. So, all of those diseases I've just spoken about are diseases caused by environmental triggers. Whereas idiopathic pulmonary fibrosis we see in patients who haven't had those environmental exposures. They haven't been working on, you know, carpentry or cutting tabletops with synthetic marble products, or have they been smokers, nor have they ever been exposed to asbestos or any other environmental factor that we would usually associate with lung disease and yet the patients have this horrible, progressive, nasty scarring disease called idiopathic pulmonary fibrosis. And as I mentioned, there are approved drugs on the market, but those drugs do not reverse the fibrosis. So, at the moment, you know, a patient that has idiopathic pulmonary fibrosis has a median survival time of about two to five years. And that timeline is really not extended a huge amount on the drugs that are approved already. And that's because they do slow the progression, but they're not stopping or reversing the fibrosis. And so, the patient continues to have a poor quality of life and is continually affected by the disease. And we see in our preclinical model that the drug VB0004 that we've been talking about has the seems to have the ability to actually reverse the fibrosis. So not just slowing down the disease progression, but actually turning that scarring around and headed back towards what we consider normal lung architecture. So really exciting times for us here at Vectus.
Andrew Musgrave
And can I ask, why has Vectus chosen IPF as the lead indication, given the compound has also shown potential in heart and kidney fibrosis?
Tara Speranza
Yeah, so and I was mentioning before that heart and kidney fibrosis are very big diseases, and these are diseases that affect a lot of people, which means that when you move forward through the clinical development stage, you need to be recruiting lots of patients into those arms on the study. So that increases the cost of the clinical trials, and it increases the requirement to recruit patients, which we all know can sometimes be a rate-limiting step in clinical trials. And you also don't get some of the handholding from the regulatory agents that you do when you're looking at a rare disease or a disease that the FDA or the EMA designate as an orphan disease, with and you have an orphan drug to treat to potentially treat that disease. So, we did it from a strategic point of view, but also because this disease is really an unmet need. And the more I spoke to clinicians and KOLs in the field, the more I realized that these patients are, you know, crying out for something new. And, you know, the families of these patients are desperate to find something to improve the quality of life and the lungs in these patients.
Andrew Musgrave
The FDA has recently granted Vectus a pre-IND type B meeting for VB0004 in IPF with written responses expected by mid-November. Why is this such an important step? And what are you hoping to get clarity on?
Tara Speranza
So, what this means for us is that the FDA have taken a look at our package that we provided them to request this meeting and thought about it and discussed amongst the various subject matter experts there at the FDA and have decided that yes, our drug has a potential to treat the disease. And therefore, yes, they're willing to provide us with some important details about what they think might be of use to us as we push the drug through that regulatory pathway. So, the things that we want clarity from them are our pre-clinical work to make sure that we've covered all the bases of the pre-clinical studies that would be required by the FDA to consider this a drug that has the potential to treat the disease. We're also making sure our CMC, or our chemistry manufacturing and controls are all in place. So that's you know, all of the production of the drug itself and all of the technical things required to make and get this drug into our clinical trials and patients, hopefully, in the future as we move forward. And so, the FDA will give us clarity around all of those sorts of things and we're in a lucky position actually that we have also run a first-in-human study in healthy patients and a very small handful of hypertensive patients as well. So, we can actually present even the clinical data or the clinical outcomes of that initial safety trial to the FDA at this very, very early stage. And so, they can give us feedback about, you know, how that looks and what it means for our development pathway as we move forward. And hopefully, you know, going forward, we get an IND, and that means we can start to trial the drug in patients over in the US as well as here in Australia.
Andrew Musgrave
Now you've appointed Cardinal Health Regulatory Services as your US agent after year end. So, what real role will they play and why was having that capability in place so important?
Tara Speranza
I think having the capability in place is extremely important for all companies looking to work with the FDA and the EMA eventually as well. So Cardinal Health, you know, provide us with the whole plethora of the subject matter experts that we are going to require as we talk to the FDA and the FDA asks questions of us as well. So any company that's not registered or licensed in the US and wants to move through the FDA processes need a US-based agent anyway and so choosing Cardinal Health was a no-brainer for us given you know their expertise in all of the particular themes that we need to be talking to the FDA about when we move our drugs through those regulatory frameworks, so to speak. And to date, the guys at Cardinal Health, you know, I consider them part of the team now. We meet so often, and we work so well and, in such detail, together, in such granular detail together. And together we you know package all of the required elements of each of the sections as we work through, like I said, that regulatory pathway. So, it's a big job getting your packages together for the FDA. And I, you know, wouldn't be able to do it without them. I think they've just been terrific.
Andrew Musgrave
Looking now at your pipeline, Vectus has a drug library of more than 1,000 small molecule candidates targeting cardiovascular, renal, and liver fibrosis. How do you decide which assets to advance, which to partner, and which to hold?
Tara Speranza
Yeah, so and you forgot lung in there too. So, lung is the first one, actually. We are we have done some cell-based in vitro assays for a collection of those molecules already. So, there are four molecules that really came through as showing particularly potent activity in our cell-based assays, and those four have gone on to animal studies. And in within each of those four, they're all part of a portfolio, a family of drugs that are related to them from a structural or chemical point of view and so we have a couple of others that have come through to the animal studies as well. And so, we use the gold standard models for each of the animal models of those diseases that you talked about. So, lung fibrosis, kidney and heart fibrosis, and then liver fibrosis. So, the, you know, they actually are different animal models that you use to replicate those diseases, and then of course, hypertensive models as well. So, we then go and test those drugs at various doses in the animal studies too. But I understand what you're asking is even further back from that, what are we going to do now that we've got so many as we look forward and decide which are the next molecules to come through? And I think that's one of the exciting things that we can use AI for, where we can use some AI modelling to predict which of our huge number of molecules might be the most exciting ones to bring forward through to those first in vitro assays and then into the animal studies. But for now we've got four that have shown significant potential and have had interest. In fact, one of those four is the one that the Canadian company licensed out already at the preclinical, at the preclinical level. So again, already showing such good promise and you know, having those guys licensed that at that drug out has really validated the science behind the way that our molecules work and the potential that they have for treating the diseases. Moving forward, one thing we're really excited about is engaging with some of these really good language models that help to predict drug efficacy and target engagement of our drugs. And I think that's probably the way we're going to be able to move molecules through. So, the company's been around for a while and it's taken us this long to get to where we are with our lead asset, VB0004 but we really think the one thing that AI will be of use for with us is to make that pathway of a lot faster and a lot quicker.
Andrew Musgrave
Finally, Tara, what are some of the key milestone’s investors should be watching out for over the next 12 months and what would success look like for Vectus by this time next year?
Tara Speranza
Yeah, so the milestones we've got coming up are pretty straightforward and very exciting. The first one, of course, being the feedback from the FDA regarding our pre-IND meeting. And then after that, of course, we're going to move forward in packaging the actual IND request. The orphan drug designation request, we should have some information or some announcements around that towards the end of the year. And the next big one, of course, is going to be our clinical trial. So, we're prepping now as we speak for the next clinical trial. This is going to be an adaptive phase 1B/2A trial. So, the 1B part will be in healthy volunteers, and we're going to increase the dose. So, we're going to push the dose up to a much higher dose than we did in our previous trial, and then we'll adapt straight into our patient study. So, a small group of patients that have IPF, and we're going to see how they fare with the drug for a small period of time. So that's our phase 1B/2A clinical trial that I'm particularly excited about as we enter the next couple of months. So, we're looking to try and get that up and running and underway in the first quarter of next calendar year. So, this time next year, I would like to think that we have completed and analysed a lot of the data and talking to the FDA about what it looks like moving forward and what kinds of trials we might require after those first trials in the patients. And so that way we can expand our trial, increase the number of patients on our arms, and potentially open up new sites around the world and move forward to get this the progress of VB0004 up and running and closer to market.
Andrew Musgrave
Okay, Tara. Well, it's been great to have you on the podcast today. So, thanks for your time and we will watch your progress with interest.
Tara Speranza
Amazing. Thank you so much for having me, Andrew. Lovely to see you again, too.
Andrew Musgrave
That concludes this episode of ASX Brief. Don't forget to subscribe, and we look forward to catching you on our next episode.